![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
WEST LAFAYETTE, Ind., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) (βEndocyteβ), a biopharmaceutical company developing targeted therapeutics for cancer treatment, today...
Entered into agreement and plan of merger with Novartis AG for $2.1BillionΒ Β Β Β Β Β Β Β Β WEST LAFAYETTE, Ind., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a...
By Denise Roland and Donato Paolo Mancini This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street...
By Charley Grant How do you earn an investment return that would make even the luckiest bitcoin speculator blush? One biotech company has the answer. Endocyte announced Thursday it would sell...
By Denise Roland and Donato Paolo Mancini Novartis AG on Thursday said it would pay $2.1 billion for Endocyte Inc., a U.S. company developing a new treatment for prostate cancer, the Swiss...
By Denise Roland and Donato Paolo Mancini Novartis AG on Thursday said it would pay $2.1 billion for Endocyte Inc., a U.S. company developing a new treatment for prostate cancer, the Swiss...
By Donato Paolo Mancini Novartis AG on Thursday said it would buy cancer-drug maker Endocyte Inc. for $2.1 billion, the Swiss pharmaceutical giant's latest move to refocus on higher-value...
By Donato Paolo Mancini Novartis AG (NOVN.EB) raised its outlook on Thursday, and announced it would acquire radiopharmaceuticals company Endocyte Inc. (ECYT) in a deal that values it at $2.1...
Novartis to acquire Endocyte for $24 per fully diluted share in cash PSMA-617 to enhance Novartisβ industry-leading radio-ligand therapy platform WEST LAFAYETTE, Ind., Oct. 18, 2018 (GLOBE...
West Lafayette, Ind., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Endocyte Inc.Β (Nasdaq:Β ECYT),Β reached a milestoneΒ this year when its value recently reached aboutΒ $1.5Β billionΒ and as the companyβsΒ drug...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions